Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
loxoprofen sodium + methocarbamol is an oral fixed-dose combination drug used for relief of acute musculoskeletal pain and spasms. **Loxoprofen sodium** is a nonsteroidal anti-inflammatory drug (NSAID) that acts as an analgesic and anti-inflammatory agent by non-selectively inhibiting cyclooxygenase (COX) enzymes, thus reducing prostaglandin synthesis. **Methocarbamol** is a centrally acting skeletal muscle relaxant that provides relief from muscle spasms and pain, likely by depressing nerve transmission in the spinal cord, though its exact mechanism is not fully understood. The two drugs act additively without pharmacokinetic interaction, independently providing pain relief and muscle relaxation. This fixed-dose combination is primarily used for acute painful musculoskeletal conditions such as back pain, especially after trauma or strain, and is administered orally in film-coated tablet form[3][1]. The combination has been marketed and trialed as a fixed dose product in Japan and possibly other regions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on loxoprofen sodium + methocarbamol.